Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.68 |
| ▸ | CDK4 | P11802 | 7/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.52 |
| ▸ | CCND1 | P24385 | 7/20 | 0.52 |
| ▸ | CDK2 | P24941 | 7/20 | 0.52 |
| ▸ | CCND3 | P30281 | 7/20 | 0.52 |
| ▸ | JAK2 | O60674 | 5/20 | 0.50 |
| ▸ | JAK1 | P23458 | 5/20 | 0.50 |
| ▸ | TYK2 | P29597 | 5/20 | 0.50 |
| ▸ | JAK3 | P52333 | 5/20 | 0.50 |
| ▸ | MAP3K8 | P41279 | 4/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011766 | 0.83 | ITK (0.54) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL12813359 | 0.81 | PDPK1 (1.00) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5523267 | 0.79 | CDK4 (0.69) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5518740 | 0.79 | CDK4 (0.64) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL3533024 | 0.77 | PDPK1 (0.73) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5953022 | 0.77 | PDPK1 (0.62) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5514172 | 0.77 | PDPK1 (0.64) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5514612 | 0.77 | PDPK1 (0.61) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5515337 | 0.77 | CDK4 (0.85) | PDPK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5508107 | 0.75 | CDK4 (0.60) | PDPK1CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | claimed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PDPK1 61/4885CDK4 84/4885CCNA2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.